(Q41962477)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19259293%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

editorial

0 references

title

Neuroendocrine tumors: is there a standard treatment? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19259293%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

author name string

Matthew H Kulke

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19259293%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

publication date

1 May 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19259293%20AND%20SRC:MED&resulttype=core&format=json

Gastrointestinal cancer research : GCR

22 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19259293%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

volume

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19259293%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19259293%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

page(s)

152-153

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19259293%20AND%20SRC:MED&resulttype=core&format=json

Biology and treatment of metastatic gastrointestinal neuroendocrine tumors.

22 January 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2633073

Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2633073

A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2633073

Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2633073

In situ radiotherapy with 111In-pentetreotide: initial observations and future directions.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2633073

Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2633073

Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2633073

Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2633073

Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2633073

90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2633073

Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2633073

Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2633073

High-dose indium 111In pentetreotide radiotherapy for metastatic atypical carcinoid tumor

18 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19259293

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Long-term efficacy of high-activity 111in-pentetreotide therapy in patients with disseminated neuroendocrine tumors

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19259293

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Expression of vascular endothelial growth factor in digestive neuroendocrine tumours

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19259293

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19259293%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

PubMed publication ID

19259293

1 reference